Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems

被引:5
作者
Vazzano, Jennifer [1 ]
Frankel, Wendy L. [1 ]
Wolfe, Adam R. [2 ]
Williams, Terence M. [2 ]
Chen, Wei [1 ]
机构
[1] Ohio State Univ, Dept Pathol, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Radiat Oncol, Wexner Med Ctr, Columbus, OH 43210 USA
关键词
Pancreatic cancer; Neoadjuvant therapy; Morphology; Tumor regression grade; PREOPERATIVE CHEMORADIATION; THERAPY; CHEMORADIOTHERAPY; PATHOLOGY; SURVIVAL; CANCER;
D O I
10.1016/j.humpath.2020.11.010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is aggressive, with an overall five-year survival rate of 9%, and few patients are candidates for pancreatectomy at presentation. The role of neoadjuvant therapy (NAT) is evolving, especially for high-risk potentially resectable tumors. Owing to the increasing number of NAT resection specimens, we aim to characterize the histologic changes associated with NAT and to compare two tumor regression grading schemes. One hundred eighteen resections for PDAC were selected from the cases between 2011 and 2018, 59 not treated and 59 treated with NAT. All H&E stained tumor slides were reviewed for histologic changes and graded using the four-tier modified Ryan score (recommended by College of American Pathologists) and the three-tier MD Anderson (MDA) score. The histologic changes evaluated included blue/grey fibrosis, islet cell hyperplasia, dystrophic calcification, amyloid deposition, cholesterol clefts, nerve hypertrophy, elastotic stromal/vascular change, abscess formation, and eosinophilic tumor cell changes. There were statistically significant differences for dystrophic calcification, eosinophilic tumor cell changes, elastotic stromal/vascular change, islet cell hyperplasia, and nerve hypertrophy between the two groups, with these features seen more frequently in NAT cases. Blue/grey stromal fibrosis was present in all cases regardless of NAT, except few complete regression cases and one treated case with intraneural invasion only. Blue/grey fibrosis is a useful histologic visual clue to suggest the possibility of adjacent tumor in the majority of PDAC cases regardless of NAT. By Kaplan-Meier analysis, neither grading scheme correlated with overall survival in our cohort. However, the MDA score was significantly correlated with both time to primary tumor recurrence (p = 0.002) and time to distant recurrence (p = 0.04), whereas the modified Ryan score was not. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 22 条
  • [1] The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma
    Abbott, Daniel E.
    Tzeng, Ching-Wei David
    Merkow, Ryan P.
    Cantor, Scott B.
    Chang, George J.
    Katz, Matthew Harold
    Bentrem, David J.
    Bilimoria, Karl Y.
    Crane, Christopher H.
    Varadhachary, Gauri R.
    Abbruzzese, James L.
    Wolff, Robert A.
    Lee, Jeffrey E.
    Evans, Douglas B.
    Fleming, Jason B.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S500 - S508
  • [2] [Anonymous], 2010, PROTOCOL EXAMINATION
  • [3] Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma
    Chatterjee, Deyali
    Katz, Matthew H.
    Rashid, Asif
    Varadhachary, Gauri R.
    Wolff, Robert A.
    Wang, Hua
    Lee, Jeffrey E.
    Pisters, Peter W. T.
    Vauthey, Jean-Nicolas
    Crane, Christopher
    Gomez, Henry F.
    Abbruzzese, James L.
    Fleming, Jason B.
    Wang, Huamin
    [J]. CANCER, 2012, 118 (12) : 3182 - 3190
  • [4] The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer
    Crane, CH
    Varadhachary, G
    Wolff, RA
    Pisters, PWT
    Evans, DB
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2006, 20 (02) : 365 - 382
  • [5] Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation
    Estrella, Jeannelyn S.
    Rashid, Asif
    Fleming, Jason B.
    Katz, Matthew H.
    Lee, Jeffrey E.
    Wolf, Robert A.
    Varadhachary, Gauri R.
    Pisters, Peter W. T.
    Abdalla, Eddie K.
    Vauthey, Jean-Nicolas
    Wang, Hua
    Gomez, Henry F.
    Evans, Douglas B.
    Abbruzzese, James L.
    Wang, Huamin
    [J]. CANCER, 2012, 118 (01) : 268 - 277
  • [6] EVANS DB, 1992, ARCH SURG-CHICAGO, V127, P1335
  • [7] Ishikawa O, 1988, Nihon Gan Chiryo Gakkai Shi, V23, P720
  • [8] Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study
    Kalimuthu, Sangeetha N.
    Serra, Stefano
    Dhani, Neesha
    Hafezi-Bakhtiari, Sara
    Szentgyorgyi, Eva
    Vajpeyi, Rajkumar
    Chetty, Runjan
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2017, 70 (03) : 237 - 243
  • [9] Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma
    Katz, Matthew H. G.
    Wang, Huamin
    Fleming, Jason B.
    Sun, Charlotte C.
    Hwang, Rosa F.
    Wolff, Robert A.
    Varadhachary, Gauri
    Abbruzzese, James L.
    Crane, Christopher H.
    Krishnan, Sunil
    Vauthey, Jean-Nicolas
    Abdalla, Eddie K.
    Lee, Jeffrey E.
    Pisters, Peter W. T.
    Evans, Douglas B.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (04) : 836 - 847
  • [10] Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation Would Fewer Tier-Stratification Be Favorable Toward Standardization?
    Kim, Sunhee S.
    Ko, Andrew H.
    Nakakura, Eric K.
    Wang, Zhen J.
    Corvera, Carlos U.
    Harris, Hobart W.
    Kirkwood, Kimberly S.
    Hirose, Ryutaro
    Tempero, Margaret A.
    Kim, Grace E.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2019, 43 (03) : 334 - 340